Novartis' Zometa Adds Warning On Renal Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling recommends dosing should be decreased for patients with mild-to-moderate renal impairment, based on the patient's creatinine clearance levels. Novartis recommends identification and management of "factors predisposing of renal deterioration."
You may also be interested in...
Zometa Label Adds Osteonecrosis Of The Jaw Precaution
Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.